ARWR - Arrowhead Pharmaceuticals Inc.
IEX Last Trade
23.82
-0.260 -1.092%
Share volume: 1,230,224
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$24.08
-0.26
-1.08%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-08-04 | 2022-11-28 | 2023-02-06 | 2023-05-02 | 2023-08-07 | 2023-11-29 | 2024-02-06 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 751.782 M | 691.939 M | 891.489 M | 891.308 M | 795.856 M | 765.552 M | 626.286 M | 955.150 M | |
| Current Assets | 432.388 M | 405.299 M | 574.999 M | 574.810 M | 470.165 M | 419.521 M | 237.899 M | 541.650 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 15.653 M | 27.493 M | 33.600 M | 24.371 M | 17.215 M | 15.895 M | 17.620 M | 18.536 M | |
| Short Term Investments | 15.653 M | 27.493 M | 33.600 M | 24.371 M | 17.215 M | 15.895 M | 17.620 M | 18.536 M | |
| Total Receivables | 239.000 K | 1.410 M | 39.568 M | 69.434 M | 1.247 M | 0.000 | 0.000 | 0.000 | |
| Current Cash | 416.496 M | 376.396 M | 501.831 M | 481.005 M | 451.703 M | 403.626 M | 220.279 M | 523.114 M | |
| Total Non-current Assets | 319.394 M | 286.640 M | 316.490 M | 316.498 M | 325.691 M | 346.031 M | 388.387 M | 413.500 M | |
| Property Plant Equipment | 71.904 M | 110.297 M | 147.314 M | 185.228 M | 231.369 M | 290.262 M | 333.411 M | 359.252 M | |
| Other Assets | 275.000 K | 218.000 K | 210.000 K | 210.000 K | 210.000 K | 210.000 K | 232.000 K | 210.000 K | |
| Intangible Assets | 12.387 M | 11.962 M | 11.537 M | 11.112 M | 10.687 M | 10.262 M | 9.837 M | 9.412 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 751.782 M | 691.939 M | 891.489 M | 891.308 M | 795.856 M | 765.552 M | 626.286 M | 955.150 M | |
| Total liabilities | 277.605 M | 293.419 M | 514.450 M | 444.536 M | 431.026 M | 494.209 M | 465.879 M | 471.356 M | |
| Total current liabilities | 128.212 M | 138.850 M | 122.009 M | 87.151 M | 70.227 M | 105.456 M | 63.723 M | 65.175 M | |
| Accounts Payable | 5.894 M | 2.868 M | 796.000 K | 9.556 M | 7.874 M | 35.866 M | 4.460 M | 8.521 M | |
| Other liabilities | 71.162 M | 55.950 M | 293.638 M | 258.981 M | 263.733 M | 268.326 M | 273.692 M | 280.938 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 71.162 M | 55.950 M | 293.638 M | 258.981 M | 263.733 M | 268.326 M | 273.692 M | 280.938 M | |
| Minority interest | 0.000 | 19.819 M | 19.333 M | 18.334 M | 17.155 M | 15.819 M | 13.307 M | 11.611 M | |
| Total Shareholder equity | 474.177 M | 398.520 M | 377.039 M | 446.772 M | 364.830 M | 271.343 M | 160.407 M | 483.794 M | |
| Common stock | 105.753 M | 105.872 M | 106.039 M | 106.757 M | 107.004 M | 107.200 M | 107.415 M | 123.285 M | |
| Retained earnings | -735.244 M | -820.755 M | -862.080 M | -813.405 M | -916.351 M | -1.026 B | -1.159 B | -1.284 B |